Inpatient Lurasidone Treatment for Adolescent Bipolar Depression: A Retrospective Study
- 1Department of Child and Adolescent Psychiatry, Ege University Faculty of Medicine, İzmir, Türkiye
Abstract
Background: This study aimed to describe short-term clinical outcomes and tolerability associated with lurasidone-containing treatment regimens in adolescents hospitalized for bipolar depression.
Methods: We retrospectively reviewed 28 adolescents aged 10–17 years who received lurasidone during admission to a university child and adolescent psychiatry unit between May 2024 and June 2025. All patients received at least one concurrent psychotropic treatment. Admission and discharge outcomes were assessed with the 17-item Hamilton Depression Rating Scale (HDRS), Beck Depression Inventory (BDI), and Clinical Global Impressions-Severity (CGI-S); CGI-Improvement (CGI-I), adverse events, and weight change were also recorded.
Results: Mean length of hospital stay was 22.7 days. Among patients with complete paired data, HDRS scores decreased from 23.0 to 5.7 (n = 25), BDI scores from 27.7 to 7.6 (n = 25), and CGI-S scores from 5.9 to 2.1 (n = 28). At discharge, CGI-I was 1 (very much improved) in 3 patients and 2 (much improved) in 25 patients. No manic or hypomanic switch was documented. Mean weight change was +0.85 kg. The most frequent adverse events were nausea, headache, and akathisia; one patient required temporary treatment interruption for an acute oculogyric crisis, but no patient permanently discontinued lurasidone because of an adverse event.
Conclusion: Clinical improvement was observed during hospitalization after lurasidone was introduced as part of multimodal treatment. Because the study was retrospective, uncontrolled, and universally involved polypharmacy, the independent contribution of lurasidone cannot be determined. Prospective controlled studies are needed.
Related
- Adolescent Perspectives on Parental Consent Requirements for Depression Treatment: A Mixed-Methods Investigation
- Dimension-Specific Childhood Maltreatment and Cross-Sectional Markers of Illness Burden in Treatment-Resistant Depression: A Retrospective Single-Center Study
- Repetitive transcranial magnetic stimulation for treatment-resistant depression in Singapore: a retrospective, naturalistic study
- CO002 | RETROSPECTIVE LONGITUDINAL ASSESSMENT OF JOINT HEALTH AND QUALITY OF LIFE IN ADOLESCENT AND ADULT PATIENTS AFFECTED BY MODERATE OR SEVERE HAEMOPHILIA A WITH OR WITHOUT INHIBITOR SWITCHING FROM INTRAVENOUS FVIII TREATMENT TO SUBCUTANEOUS PROPHYLAXIS WITH EMICIZUMAB
- Real-world clinical outcomes under intravenous and subcutaneous esketamine protocols for treatment-resistant depression: a multicenter, retrospective study
BibTeX
@article{ocakoglu2026inpatient,
title = {{Inpatient Lurasidone Treatment for Adolescent Bipolar Depression: A Retrospective Study}},
author = {Fevzi Tuna Ocakoğlu and Yiğit Özaydın and Merve Mergen and İpek Aksakal and Eyüp Sabri Ercan},
journal = {Psychiatry and clinical psychopharmacology},
year = {2026},
month = aug,
doi = {10.65801/pcp.3466},
url = {https://europepmc.org/article/PMC/PMC13720850},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Inpatient Lurasidone Treatment for Adolescent Bipolar Depression: A Retrospective Study
AU - Fevzi Tuna Ocakoğlu
AU - Yiğit Özaydın
AU - Merve Mergen
AU - İpek Aksakal
AU - Eyüp Sabri Ercan
PY - 2026
DA - 2026/08/01
JO - Psychiatry and clinical psychopharmacology
DO - 10.65801/pcp.3466
UR - https://europepmc.org/article/PMC/PMC13720850
AB - Background: This study aimed to describe short-term clinical outcomes and tolerability associated with lurasidone-containing treatment regimens in adolescents hospitalized for bipolar depression. Methods: We retrospectively reviewed 28 adolescents aged 10–17 years who received lurasidone during admission to a university child and adolescent psychiatry unit between May 2024 and June 2025. All patients received at least one concurrent psychotropic treatment. Admission and discharge outcomes were assessed with the 17-item Hamilton Depression Rating Scale (HDRS), Beck Depression Inventory (BDI), and Clinical Global Impressions-Severity (CGI-S); CGI-Improvement (CGI-I), adverse events, and weight change were also recorded. Results: Mean length of hospital stay was 22.7 days. Among patients with complete paired data, HDRS scores decreased from 23.0 to 5.7 (n = 25), BDI scores from 27.7 to 7.6 (n = 25), and CGI-S scores from 5.9 to 2.1 (n = 28). At discharge, CGI-I was 1 (very much improved) in 3 patients and 2 (much improved) in 25 patients. No manic or hypomanic switch was documented. Mean weight change was +0.85 kg. The most frequent adverse events were nausea, headache, and akathisia; one patient required temporary treatment interruption for an acute oculogyric crisis, but no patient permanently discontinued lurasidone because of an adverse event. Conclusion: Clinical improvement was observed during hospitalization after lurasidone was introduced as part of multimodal treatment. Because the study was retrospective, uncontrolled, and universally involved polypharmacy, the independent contribution of lurasidone cannot be determined. Prospective controlled studies are needed.
SN - 2475-0581
ER -